Navigation Links
Molecular trigger for Huntington's disease found

Researchers have discovered a key regulatory molecule whose overactivation by the abnormal protein produced in Huntington's disease (HD) causes the central pathologies of the disease. The abnormal HD protein activates the regulatory protein called p53, which in turn switches on a host of other genes. This abnormal gene activation damages the cells' power plants, called the mitochondria, and kills brain cells.

The researchers also speculated that disturbances in p53 may also play a role in some forms of Parkinson's disease and amyotrophic lateral sclerosis, or Lou Gehrig's disease.

Ironically, p53 is the same regulatory protein that is inactivated in a large fraction of cancers. This inactivation allows abnormal cancer cells to escape the cell's protective "suicide program" that would normally kill them. The researchers theorize that the lower incidence of cancer in HD patients could be caused by the protective effect of overactive p53.

In the July 7, 2005, issue of Neuron, Akira Sawa and colleagues at Johns Hopkins University School of Medicine reported experiments ranging from molecular studies in cultured brain cells to analysis of the brains of human HD patients that demonstrated the central role of p53 in the pathologies of HD.

Their studies with cell cultures showed that the abnormal HD protein selectively binds to p53 and increases its level in cells. They noted that the brains of patients with HD also show substantial increases in the p53 protein, with the highest levels in cases with the most extensive pathology.

The researchers' experiments also revealed that this p53 increase causes an overactivation in the genes regulated by p53, which is called a "nuclear transcription factor" because it regulates the transcription of its target genes in cell nuclei.

In studies of cell cultures and of mice engineered to have HD, the researchers found that the p53 increase causes malfunctions in mitochondria. What's more, the
'"/>

Source:Cell Press


Page: 1 2

Related biology news :

1. Molecular biology fills gaps in knowledge of bat evolution
2. Molecular machine may lead to new drugs to combat human diseases
3. Molecular Motors Cooperate In Moving Cellular Cargo, Study Shows
4. Molecular models advance the fight against malaria
5. Molecular fossils uncover link between viruses and the immune system
6. Molecular thermometers on skin cells detect heat and camphor
7. Molecular messengers perform a crucial role in the ability of injured nerve cells to heal themselves
8. Molecular steps involved in the creation of gene-silencing microRNAs identified
9. Molecular miners find pain relief drugs from the sea
10. Molecular mechanism of feather formation found
11. Molecular Partners Required For Appropriate Neuronal Gene Repression
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Molecular trigger for Huntington disease found

(Date:5/18/2015)... , May 18, 2015 Fingerprint ... sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if ... June until and including Q3 2015 and the sensors will ... . Communicated order values for 2015 hereby amount to 740 ... Q1 2015 of 140 MSEK and a number of smaller ...
(Date:5/11/2015)... May 11, 2015 Curemark LLC, a privately ... of a new Phase III double blind, randomized, placebo-controlled ... formulation, CM-AT, on all children ages 3-8 with Autism. ... Phase III double blinded clinical trial for CM-AT in ... of the digestive enzyme chymotrypsin. This new trial will ...
(Date:5/5/2015)... 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, reminds investors and media that ... is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series ... is themed Global Fraud: Where is the Trust in ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... UC Davis cancer researchers have found that older men ... regular CT scans over lymph node removal are at ... last week in the journal Cancer, indicate that physicians ... when discussing treatment options with their patients. ...
... University of Washington physicists are detecting radioactivity from ... a mammoth March 11 earthquake, but the levels are ... health. On March 16, the scientists began testing ... Building on the UW campus, looking for evidence of ...
... is available in German . , Innovations relating ... presented by KIT at the 2011 Hannover Messe from April ... KIT will present a hybrid Porsche racing car, developments in ... InnoEnergy for a European energy supply system, and the Energy ...
Cached Biology News:Frequent CT scanning for testicular cancer surveillance associated with secondary malignancies 2Frequent CT scanning for testicular cancer surveillance associated with secondary malignancies 3Physicists detect low-level radioactivity from Japan arriving in Seattle 2Physicists detect low-level radioactivity from Japan arriving in Seattle 3KIT presents innovations at the 2011 Hannover Messe 2KIT presents innovations at the 2011 Hannover Messe 3KIT presents innovations at the 2011 Hannover Messe 4KIT presents innovations at the 2011 Hannover Messe 5
(Date:6/2/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/7264hm/biomarkers ) ... report "Biomarkers - Technologies, Markets and Companies" ... follows the broad definition of a biomarker as ... evaluated as an indicator of normal biological or ... a therapeutic intervention. Tests based on biomarkers have ...
(Date:6/2/2015)... June 02, 2015 Research and Markets( http://www.researchandmarkets.com/research/l5jcdk/genotyping_market ... Market by Technology, Application & by Products - Global ... The global genotyping market is expected to reach ... at a CAGR of 22.3% during the forecast period ... be attributed to the availability of a range of ...
(Date:6/2/2015)... PAULO , June 2, 2015   Hospira, ... in biosimilars, today announced that its partner, Celltrion – a ... – the National Health Surveillance Agency in ... biosimilar monoclonal antibody approved for use in ... Hospira. Hospira also markets and sells biosimilar infliximab in ...
(Date:6/2/2015)... June 02, 2015 “Stem Cell Therapy to ... mainstream, and it is used often as an adjunct to ... practitioners are not yet aware or comfortable enough with the ... is most often reserved for the last resort cases - ... can barely lift a paw to get around. It is ...
Breaking Biology Technology:Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 3Genotyping Market Report 2015 by Technology, Application & by Products - Global Forecast to 2020 for the $17 Billion Market 2ANVISA Approves First Infliximab Biosimilar in Brazil 2ANVISA Approves First Infliximab Biosimilar in Brazil 3ANVISA Approves First Infliximab Biosimilar in Brazil 4ANVISA Approves First Infliximab Biosimilar in Brazil 5VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 2VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 3
... N.J., Sept. 21 Nuvilex, Inc. (OTC Bulletin Board: NVLX), ... with Reme-Flu(TM), will be incorporating Syn-X9(TM) proprietary delivery technology into ... to help prevent and treat flu-type symptoms resulting from influenza-like ... , , The unique attributes of the ...
... , ATLANTA, Sept. 21 CryoLife, Inc. (NYSE: ... to suburban Atlanta this week for the two-day Ross Summit ... of the Ross Procedure and to practice the technical nuances required to perform ... The Ross Procedure is a type of specialized aortic valve surgery in ...
... Mass., Sept. 21 Merrimack Pharmaceuticals, Inc., announced today that ... President, Development. Dr. Niyikiza comes to Merrimack from GlaxoSmithKline (GSK) ... oncology. Dr. Niyikiza has extensive drug development experience with ... pharmaceutical industry in which he has led ten New Drug ...
Cached Biology Technology:Nuvilex, Inc. Announced that Reme-Flu(TM) will Incorporate Proprietary Syn-X9(TM) Delivery Technology into its Product Formulation 2Nuvilex, Inc. Announced that Reme-Flu(TM) will Incorporate Proprietary Syn-X9(TM) Delivery Technology into its Product Formulation 3Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual Summit 2Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual Summit 3Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual Summit 4Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual Summit 5Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development 2
Eagle's Ham's amino acids; EHAA...
... active ingredient in Molecular Probes. SlowFadeAntifade ... to act as a free radical ... Our original SlowFade formulation (S-2828) was ... of fluorescein to almost zero (Figure ...
... System more than doubles the benefits of ... fast analysis cycles of the standard binary ... in tandem mode. Difficult separations are dramatically ... or heartcut configurations, on-line sample preparation is ...
... The PerkinElmer kit provides reagents for ... in serum and plasma samples using a ... samples are then neutralized and transferred to ... highly specific mouse monoclonal antibody to HIV-1 ...
Biology Products: